| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle, Smooth, Vascular | 6 | 2013 | 63 | 1.040 |
Why?
|
| Myocytes, Smooth Muscle | 4 | 2013 | 72 | 0.770 |
Why?
|
| Carotid Arteries | 6 | 2013 | 99 | 0.640 |
Why?
|
| Blood Vessel Prosthesis | 4 | 2012 | 83 | 0.600 |
Why?
|
| Tunica Intima | 5 | 2005 | 57 | 0.550 |
Why?
|
| Endothelial Cells | 5 | 2012 | 189 | 0.530 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 45 | 0.440 |
Why?
|
| RGS Proteins | 4 | 2007 | 18 | 0.440 |
Why?
|
| Hyaluronic Acid | 1 | 2013 | 52 | 0.440 |
Why?
|
| Carotid Stenosis | 1 | 2013 | 58 | 0.430 |
Why?
|
| Tissue Scaffolds | 4 | 2012 | 415 | 0.380 |
Why?
|
| Tissue Engineering | 3 | 2012 | 656 | 0.360 |
Why?
|
| Stem Cells | 2 | 2010 | 313 | 0.350 |
Why?
|
| Stents | 3 | 2009 | 178 | 0.320 |
Why?
|
| Blood Vessels | 2 | 2008 | 49 | 0.310 |
Why?
|
| Arteriosclerosis | 3 | 2004 | 122 | 0.310 |
Why?
|
| Venous Thrombosis | 3 | 2019 | 49 | 0.300 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2012 | 70 | 0.280 |
Why?
|
| Cells, Cultured | 6 | 2013 | 833 | 0.280 |
Why?
|
| Animals | 13 | 2020 | 7466 | 0.260 |
Why?
|
| Gene Expression Profiling | 2 | 2005 | 323 | 0.250 |
Why?
|
| Iliac Artery | 2 | 2002 | 49 | 0.250 |
Why?
|
| Enzyme Inhibitors | 2 | 2004 | 165 | 0.240 |
Why?
|
| Catheterization | 2 | 2019 | 58 | 0.240 |
Why?
|
| Popliteal Vein | 2 | 2019 | 3 | 0.240 |
Why?
|
| Femoral Vein | 2 | 2019 | 9 | 0.240 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2004 | 2 | 0.230 |
Why?
|
| Protein-Serine-Threonine Kinases | 1 | 2004 | 50 | 0.230 |
Why?
|
| Renal Dialysis | 2 | 2019 | 279 | 0.220 |
Why?
|
| Hyperplasia | 3 | 2013 | 38 | 0.220 |
Why?
|
| Time Factors | 8 | 2013 | 2152 | 0.220 |
Why?
|
| Genes | 1 | 2002 | 15 | 0.220 |
Why?
|
| Cell Adhesion | 3 | 2013 | 108 | 0.220 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 161 | 0.210 |
Why?
|
| Metalloendopeptidases | 1 | 2002 | 11 | 0.200 |
Why?
|
| Hydroxamic Acids | 1 | 2002 | 21 | 0.200 |
Why?
|
| Jugular Veins | 2 | 2012 | 26 | 0.190 |
Why?
|
| Neovascularization, Physiologic | 1 | 2002 | 110 | 0.190 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2012 | 48 | 0.190 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2020 | 18 | 0.180 |
Why?
|
| Drug Carriers | 1 | 2020 | 21 | 0.180 |
Why?
|
| Aorta | 3 | 2007 | 125 | 0.180 |
Why?
|
| Keratosis | 1 | 2020 | 23 | 0.180 |
Why?
|
| Vascular Surgical Procedures | 3 | 2013 | 90 | 0.170 |
Why?
|
| Sheep | 5 | 2012 | 233 | 0.170 |
Why?
|
| Biomedical Research | 2 | 2013 | 155 | 0.170 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 104 | 0.170 |
Why?
|
| Collagen Type I | 2 | 2013 | 42 | 0.160 |
Why?
|
| Patient Selection | 2 | 2019 | 277 | 0.160 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 63 | 0.160 |
Why?
|
| Vascular Diseases | 2 | 2013 | 66 | 0.160 |
Why?
|
| Prosthesis Design | 4 | 2012 | 97 | 0.150 |
Why?
|
| Cardiovascular Agents | 2 | 2020 | 23 | 0.150 |
Why?
|
| Renal Artery Obstruction | 2 | 2009 | 41 | 0.150 |
Why?
|
| Macaca fascicularis | 3 | 2004 | 397 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 2 | 2013 | 766 | 0.140 |
Why?
|
| Pulsatile Flow | 3 | 2012 | 26 | 0.140 |
Why?
|
| Bioreactors | 3 | 2012 | 60 | 0.140 |
Why?
|
| Renal Artery | 2 | 2006 | 47 | 0.130 |
Why?
|
| Collagen | 2 | 2008 | 225 | 0.130 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 607 | 0.120 |
Why?
|
| Tyrosine | 2 | 2004 | 23 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 541 | 0.120 |
Why?
|
| Angioplasty, Balloon | 2 | 2020 | 35 | 0.110 |
Why?
|
| Stress, Mechanical | 2 | 2012 | 92 | 0.110 |
Why?
|
| Cell Shape | 1 | 2013 | 28 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2012 | 24 | 0.110 |
Why?
|
| Lipoproteins, HDL | 2 | 2007 | 251 | 0.110 |
Why?
|
| Mice | 2 | 2013 | 2475 | 0.110 |
Why?
|
| Health Priorities | 1 | 2013 | 15 | 0.110 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 25 | 0.110 |
Why?
|
| Rats | 3 | 2013 | 1596 | 0.110 |
Why?
|
| Cell Culture Techniques | 2 | 2012 | 174 | 0.110 |
Why?
|
| Recurrence | 1 | 2013 | 265 | 0.100 |
Why?
|
| Materials Testing | 2 | 2012 | 89 | 0.100 |
Why?
|
| Cell Movement | 1 | 2013 | 170 | 0.100 |
Why?
|
| Anticoagulants | 2 | 2019 | 123 | 0.100 |
Why?
|
| Male | 14 | 2019 | 19196 | 0.100 |
Why?
|
| Vascular Patency | 5 | 2012 | 69 | 0.100 |
Why?
|
| Coronary Artery Disease | 2 | 2007 | 401 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2013 | 162 | 0.100 |
Why?
|
| Mice, Knockout | 1 | 2013 | 444 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2010 | 292 | 0.100 |
Why?
|
| Stem Cell Transplantation | 2 | 2012 | 209 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2013 | 687 | 0.100 |
Why?
|
| Vasoconstriction | 2 | 2011 | 41 | 0.100 |
Why?
|
| Hemodynamics | 1 | 2012 | 155 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2007 | 508 | 0.100 |
Why?
|
| Female | 13 | 2019 | 19954 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 745 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2010 | 599 | 0.090 |
Why?
|
| Bioprosthesis | 1 | 2011 | 58 | 0.090 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2010 | 6 | 0.090 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2010 | 27 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2010 | 36 | 0.090 |
Why?
|
| Immunohistochemistry | 4 | 2020 | 532 | 0.090 |
Why?
|
| Hypertension | 3 | 2007 | 957 | 0.090 |
Why?
|
| Clinical Medicine | 1 | 2009 | 12 | 0.080 |
Why?
|
| Angioplasty | 1 | 2009 | 34 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 1017 | 0.080 |
Why?
|
| Swine | 1 | 2010 | 215 | 0.080 |
Why?
|
| Polyesters | 1 | 2008 | 76 | 0.080 |
Why?
|
| Constriction, Pathologic | 2 | 2012 | 46 | 0.080 |
Why?
|
| Regional Blood Flow | 2 | 2012 | 86 | 0.080 |
Why?
|
| Peroxidase | 2 | 2004 | 31 | 0.080 |
Why?
|
| Myosin Heavy Chains | 2 | 2011 | 89 | 0.070 |
Why?
|
| Arteries | 2 | 2004 | 67 | 0.070 |
Why?
|
| Vena Cava Filters | 1 | 2007 | 13 | 0.070 |
Why?
|
| Complement Activation | 1 | 2007 | 9 | 0.070 |
Why?
|
| Peptide Hydrolases | 1 | 2007 | 17 | 0.070 |
Why?
|
| Prosthesis Implantation | 1 | 2007 | 40 | 0.070 |
Why?
|
| Humans | 17 | 2019 | 32025 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2004 | 142 | 0.070 |
Why?
|
| Device Removal | 1 | 2007 | 33 | 0.070 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 32 | 0.070 |
Why?
|
| Iliac Vein | 1 | 2006 | 8 | 0.070 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2006 | 8 | 0.070 |
Why?
|
| Proteomics | 1 | 2007 | 94 | 0.070 |
Why?
|
| Balloon Occlusion | 1 | 2006 | 36 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2280 | 0.070 |
Why?
|
| Thrombectomy | 1 | 2006 | 73 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 629 | 0.060 |
Why?
|
| Carboxypeptidases | 1 | 2005 | 21 | 0.060 |
Why?
|
| Middle Aged | 9 | 2019 | 11868 | 0.060 |
Why?
|
| Viscera | 1 | 2004 | 17 | 0.060 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2005 | 65 | 0.060 |
Why?
|
| Hypochlorous Acid | 1 | 2004 | 2 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2005 | 114 | 0.060 |
Why?
|
| Reactive Nitrogen Species | 1 | 2004 | 5 | 0.060 |
Why?
|
| Aged | 8 | 2019 | 10340 | 0.060 |
Why?
|
| Phenotype | 2 | 2005 | 639 | 0.060 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2004 | 35 | 0.060 |
Why?
|
| Aorta, Thoracic | 1 | 2005 | 85 | 0.060 |
Why?
|
| Intestine, Small | 1 | 2004 | 40 | 0.060 |
Why?
|
| Aneurysm | 1 | 2004 | 21 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2004 | 60 | 0.060 |
Why?
|
| rho-Associated Kinases | 1 | 2004 | 7 | 0.060 |
Why?
|
| Ischemia | 1 | 2004 | 98 | 0.060 |
Why?
|
| Gels | 1 | 2004 | 31 | 0.060 |
Why?
|
| Cholesterol, HDL | 1 | 2004 | 177 | 0.060 |
Why?
|
| Anoikis | 1 | 2003 | 2 | 0.060 |
Why?
|
| Tropomyosin | 1 | 2003 | 3 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 73 | 0.060 |
Why?
|
| Myocardium | 1 | 2004 | 186 | 0.060 |
Why?
|
| Embolism | 1 | 2003 | 6 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2004 | 160 | 0.050 |
Why?
|
| Drosophila Proteins | 1 | 2003 | 45 | 0.050 |
Why?
|
| Angiotensin I | 1 | 2005 | 240 | 0.050 |
Why?
|
| RNA, Ribosomal, 28S | 1 | 2002 | 1 | 0.050 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2003 | 12 | 0.050 |
Why?
|
| Versicans | 1 | 2002 | 4 | 0.050 |
Why?
|
| Venae Cavae | 1 | 2002 | 4 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2002 | 31 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 38 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2002 | 13 | 0.050 |
Why?
|
| Retrospective Studies | 6 | 2009 | 3523 | 0.050 |
Why?
|
| Carcinoma | 1 | 2003 | 92 | 0.050 |
Why?
|
| Thrombosis | 1 | 2003 | 73 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 398 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2019 | 3317 | 0.050 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2002 | 49 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2004 | 249 | 0.050 |
Why?
|
| Mass Spectrometry | 3 | 2007 | 103 | 0.050 |
Why?
|
| Adult | 6 | 2019 | 9367 | 0.050 |
Why?
|
| Kidney | 1 | 2004 | 515 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2020 | 62 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 67 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2006 | 767 | 0.040 |
Why?
|
| Catheter-Related Infections | 1 | 2019 | 10 | 0.040 |
Why?
|
| Postthrombotic Syndrome | 1 | 2019 | 1 | 0.040 |
Why?
|
| Stockings, Compression | 1 | 2019 | 2 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 1435 | 0.040 |
Why?
|
| Fibrinolysis | 1 | 2019 | 7 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2019 | 34 | 0.040 |
Why?
|
| Catheterization, Peripheral | 1 | 2019 | 29 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 144 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 70 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2019 | 100 | 0.040 |
Why?
|
| Brain | 1 | 2004 | 950 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2019 | 224 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 761 | 0.040 |
Why?
|
| Chromatography, Liquid | 2 | 2007 | 43 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2006 | 785 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2007 | 283 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 356 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 918 | 0.030 |
Why?
|
| Incidence | 2 | 2009 | 1200 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 900 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 1125 | 0.030 |
Why?
|
| Survival Rate | 2 | 2009 | 885 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2013 | 23 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2013 | 26 | 0.030 |
Why?
|
| Quality of Life | 1 | 2019 | 933 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2012 | 6 | 0.030 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2012 | 19 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2012 | 19 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2012 | 43 | 0.030 |
Why?
|
| Punctures | 1 | 2012 | 33 | 0.030 |
Why?
|
| Needles | 1 | 2012 | 31 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2012 | 45 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 94 | 0.030 |
Why?
|
| Models, Animal | 1 | 2012 | 164 | 0.030 |
Why?
|
| Inflammation | 2 | 2007 | 540 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 2615 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 292 | 0.020 |
Why?
|
| Actins | 1 | 2011 | 52 | 0.020 |
Why?
|
| Carotid Artery, Common | 1 | 2011 | 39 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 81 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2011 | 50 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 151 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 3526 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 544 | 0.020 |
Why?
|
| Vasoconstrictor Agents | 1 | 2011 | 63 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 2009 | 18 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2009 | 15 | 0.020 |
Why?
|
| Hematology | 1 | 2009 | 8 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2009 | 46 | 0.020 |
Why?
|
| Cell Count | 1 | 2009 | 47 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 158 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 149 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2009 | 45 | 0.020 |
Why?
|
| Angiography | 1 | 2009 | 80 | 0.020 |
Why?
|
| Platelet Adhesiveness | 1 | 2008 | 14 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 195 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 209 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2009 | 103 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 207 | 0.020 |
Why?
|
| Peptides | 1 | 2009 | 119 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2007 | 26 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2012 | 845 | 0.020 |
Why?
|
| Phenylephrine | 1 | 2007 | 28 | 0.020 |
Why?
|
| Serotonin | 1 | 2007 | 37 | 0.020 |
Why?
|
| Registries | 1 | 2009 | 298 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 261 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 757 | 0.020 |
Why?
|
| Phlebography | 1 | 2007 | 26 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2007 | 98 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 76 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 76 | 0.020 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2008 | 199 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2007 | 104 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 49 | 0.020 |
Why?
|
| Tunica Media | 1 | 2005 | 28 | 0.020 |
Why?
|
| Creatinine | 1 | 2006 | 195 | 0.020 |
Why?
|
| Atenolol | 1 | 2005 | 6 | 0.020 |
Why?
|
| Hydralazine | 1 | 2005 | 7 | 0.020 |
Why?
|
| Rats, Inbred SHR | 1 | 2005 | 31 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2006 | 305 | 0.020 |
Why?
|
| Tetrazoles | 1 | 2005 | 61 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2005 | 61 | 0.020 |
Why?
|
| Mesenteric Artery, Inferior | 1 | 2004 | 2 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2005 | 61 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 65 | 0.020 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2004 | 9 | 0.020 |
Why?
|
| Imidazoles | 1 | 2005 | 91 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 80 | 0.020 |
Why?
|
| Peroxynitrous Acid | 1 | 2004 | 7 | 0.020 |
Why?
|
| Lipid Peroxides | 1 | 2004 | 8 | 0.020 |
Why?
|
| Taurine | 1 | 2004 | 6 | 0.020 |
Why?
|
| Nitrogen | 1 | 2004 | 10 | 0.020 |
Why?
|
| Epitopes | 1 | 2004 | 24 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2004 | 28 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2004 | 68 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2005 | 132 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2004 | 112 | 0.010 |
Why?
|
| Angiotensin II | 1 | 2005 | 243 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2003 | 57 | 0.010 |
Why?
|
| Oxygen | 1 | 2004 | 142 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 34 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 168 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 488 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 57 | 0.010 |
Why?
|
| Peritonitis | 1 | 2003 | 14 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 71 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2004 | 123 | 0.010 |
Why?
|
| Mesenteric Arteries | 1 | 2003 | 20 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 401 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 687 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 569 | 0.010 |
Why?
|
| Morbidity | 1 | 2003 | 99 | 0.010 |
Why?
|
| North Carolina | 1 | 2007 | 1516 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 594 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 56 | 0.010 |
Why?
|
| Random Allocation | 1 | 2002 | 220 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 494 | 0.010 |
Why?
|
| Logistic Models | 1 | 2003 | 781 | 0.010 |
Why?
|
| Length of Stay | 1 | 2002 | 318 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 1194 | 0.010 |
Why?
|
| Risk Factors | 1 | 2004 | 3869 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 4000 | 0.010 |
Why?
|